May 17, 2018
Dr. Michael Fraser, Director of the Prostate Program in the Computational Biology group at OICR, has been named a 2018 NextGen Star by the American Association for Cancer Research (AACR). Awarded to only eight researchers around the world, AACR’s NextGen Stars program recognizes outstanding early-career scientists who have made significant contributions to cancer research.
February 10, 2017
The quest for a new cancer drug often begins when a protein target is implicated as an important driver in tumourigenesis. For cancer researchers, small molecules that block or stimulate such proteins can be valuable tools in research. Not only do they help us understand the role that the protein plays in cancer biology, but they also enable researchers to demonstrate which tumours are sensitive toward inhibition or stimulation with that protein target of interest, providing early clues as for patient selection and biomarker identification. Moreover, the knowledge that a small molecule can bind to such a protein builds confidence that this target is indeed “druggable,” which can provide a powerful stimulus to initiate a sustained effort to find medicines for that target.
April 6, 2016
Toronto (April 6, 2016) – Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today congratulated Dr. John Dick on receiving the prestigious honour of being one of 11 newly elected Fellows to the AACR (American Association for Cancer Research) Academy.
Dr. Dick is a Canada Research Chair in Stem Cell Biology and Senior Scientist at the University Health Network’s Princess Margaret Cancer Centre and McEwen Centre for Regenerative Medicine and Director of the Cancer Stem Cell Program at OICR.